Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Petra Herzig"'
Autor:
Marcel P. Trefny, Nicole Kirchhammer, Priska Auf der Maur, Marina Natoli, Dominic Schmid, Markus Germann, Laura Fernandez Rodriguez, Petra Herzig, Jonas Lötscher, Maryam Akrami, Jane C. Stinchcombe, Michal A. Stanczak, Andreas Zingg, Melanie Buchi, Julien Roux, Romina Marone, Leyla Don, Didier Lardinois, Mark Wiese, Lukas T. Jeker, Mohamed Bentires-Alj, Jérémie Rossy, Daniela S. Thommen, Gillian M. Griffiths, Heinz Läubli, Christoph Hess, Alfred Zippelius
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
The efficacy of T-cell-based cancer immunotherapies can be compromised by T cell exhaustion. Here the authors develop a human ex vivo exhaustion model and, based on a CRISPR-Cas9 screen, identify SNX9 as a regulator of T cell exhaustion, showing that
Externí odkaz:
https://doaj.org/article/fdf4b11832574e5fbfe57578d57e0309
Autor:
Lisanne M. Roelofsen, Paula Voabil, Marjolein de Bruijn, Petra Herzig, Alfred Zippelius, Ton N. Schumacher, Daniela S. Thommen
Publikováno v:
STAR Protocols, Vol 4, Iss 2, Pp 102282- (2023)
Summary: The lack of suitable models currently hampers our understanding of how the tumor microenvironment responds to immunotherapy treatment. Here, we present a protocol for ex vivo culture of patient-derived tumor fragments (PDTFs). We describe th
Externí odkaz:
https://doaj.org/article/c2276a0502114ffd841cacb2749b9c77
Autor:
Benjamin Müller, Anne Bärenwaldt, Petra Herzig, Alfred Zippelius, Lara Valeska Maul, Viviane Hess, David König, Heinz Läubli
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmunotherapies have improved the prognosis of many cancer patients including patients with advanced melanoma. Immune checkpoint receptors including CTLA-4 and PD-1 have been established as main therapeutic targets for immunotherapy of me
Externí odkaz:
https://doaj.org/article/eb6fcf6691c746eba41ab6e2e230cbbe
Autor:
Alfred Zippelius, Petra Herzig, Pratiksha Gulati, Christian Klein, Marta Trüb, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Marina Natoli, Klas Hatje, Fabian Junker, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Lothar Tietze, Laura Codarri-Deak, Henry Kao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). Y
Externí odkaz:
https://doaj.org/article/d05c988c40044c0488968cfb22947d69
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Abstract Background Treatment with a combination of PD-1 and CTLA-4 targeted checkpoint inhibition has improved outcome of melanoma patients and led to durable remissions but is also associated with significant toxicities. Endocrinopathies such as th
Externí odkaz:
https://doaj.org/article/63f4a6c65bfb433da7c1eab913c0b277
Autor:
Marina Natoli, Petra Herzig, Elham Pishali Bejestani, Melanie Buchi, Reto Ritschard, G. Kenneth Lloyd, Ramon Mohanlal, James R. Tonra, Lan Huang, Viola Heinzelmann, Marta Trüb, Alfred Zippelius, Abhishek S. Kashyap
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Reprogramming tumor infiltrating myeloid cells to elicit pro-inflammatory responses is an exciting therapeutic maneouver to improve anti-tumor responses. We recently demonstrated that a distinct microtubule-targeting drug, plinabulin—a clinical-sta
Externí odkaz:
https://doaj.org/article/d21b4ca37c104d1593f619178ef9f5c2
Autor:
Alfred Zippelius, Petra Herzig, Heinz Läubli, Gieri Cathomas, Christian Klein, Marta Trüb, Franziska Uhlenbrock, Christina Claus, Martin Thelen, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Abhishek S Kashyap
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The costimulatory receptor 4-1BB (CD137, TNFRSF9) plays an important role in sustaining effective T cell immune responses and is investigated as target for cancer therapy. Systemic 4-1BB directed therapies elicit toxicity or low efficacy,
Externí odkaz:
https://doaj.org/article/812e0e185e314e829d4e8fe6aa67b3da
Autor:
Heinz Läubli, Viktor H. Koelzer, Matthias S. Matter, Petra Herzig, Béatrice Dolder Schlienger, Mark Nikolaj Wiese, Didier Lardinois, Kirsten D. Mertz, Alfred Zippelius
Publikováno v:
OncoImmunology, Vol 7, Iss 2 (2018)
Cancer immunotherapy with antibodies targeting immune checkpoints such as the PD-1/PD-L1 pathway have emerged as breakthrough treatment for multiple solid tumors with high response rates and durable remissions. Despite the benefit for patients and en
Externí odkaz:
https://doaj.org/article/798022384f2747deb8d7739f4959e7ed
Autor:
Alfred Zippelius, Didier Lardinois, Vaios Karanikas, Victor Levitsky, Spasenija Savic Prince, Wolfgang Moersig, Ozana S. Fischer, Marina Bacac, Christian Klein, Pavel Pisa, Pablo Umana, Anton Belousov, Andreas Roller, Petra Herzig, Philipp Müller, Jens Schreiner, Daniela S. Thommen
Dysfunctional T cells present in malignant lesions are characterized by a sustained and highly diverse expression of inhibitory receptors, also referred to as immune checkpoints. Yet, their relative functional significance in different cancer types r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dec2145384c4a5a58e14f99be122a0c0
https://doi.org/10.1158/2326-6066.c.6548741.v1
https://doi.org/10.1158/2326-6066.c.6548741.v1
CD40 stimulation on antigen-presenting cells (APC) allows direct activation of CD8+ cytotoxic T cells, independent of CD4+ T-cell help. Agonistic anti-CD40 antibodies have been demonstrated to induce beneficial antitumor T-cell responses in mouse mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0e46b1273b5940d0e202df0e85ae37a
https://doi.org/10.1158/2326-6066.c.6548782.v1
https://doi.org/10.1158/2326-6066.c.6548782.v1